Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $23.30
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 18, 26 |
| Canaccord Genuity |
| maintain |
| Buy |
| Buy |
| Jul 20, 26 | Needham | maintain | Buy | Buy |
| Jun 16, 26 | Canaccord Genuity | maintain | Buy | Buy |
| May 8, 26 | Citizens | maintain | Market Outperform | Market Outperform |
| May 8, 26 | Needham | maintain | Buy | Buy |
| Apr 10, 26 | Ladenburg Thalmann | upgrade | Neutral | Buy |
| Apr 7, 26 | Needham | maintain | Buy | Buy |
| Feb 13, 26 | Canaccord Genuity | maintain | Buy | Buy |
| Feb 2, 26 | Needham | maintain | Buy | Buy |
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 52.74 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 82.42 | Oscillator | Sell |
| Williams %R (14) | -23.33 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.28 (Hist 0.36) | Oscillator | Buy |
| Average Directional Index (14) | 26.11 (+DI 24.1 / -DI 17.2) | Trend | Strong Buy |
| EMA 20 | 22.73 | MA | Buy |
| SMA 20 | 22.26 | MA | Strong Buy |
| EMA 50 | 23.74 | MA | Sell |
| SMA 50 | 24.43 | MA | Strong Sell |
| SMA 200 | 29.90 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 10, 26 | Green Andrew M | officer: SVP, Regulatory and Quality | S-Sale | 11,480 @ $24.97 | $286.7K |
| Sep 2, 26 | Green Andrew M | officer: SVP, Regulatory and Quality | S-Sale | 6,510 @ $27.27 | $177.5K |
| Sep 3, 26 | Green Andrew M | officer: SVP, Regulatory and Quality | S-Sale | 1,493 @ $26.02 | $38.84K |
| Aug 19, 26 | Mackin James P | officer: President & CEO | S-Sale | 70,000 @ $28.96 | $2.03M |
| Aug 14, 26 | Green Andrew M | officer: SVP, Regulatory and Quality | S-Sale | 616 @ $28.55 | $17.59K |
| Aug 14, 26 | Berry Lance A | officer: EVP, COO, CFO & Treasurer | S-Sale | 715 @ $28.55 | $20.41K |
| Aug 12, 26 | Holloway Jean F | officer: SVP, General Counsel | S-Sale | 977 @ $28.49 | $27.83K |
| Jun 11, 26 | Green Andrew M | officer: SVP, Regulatory and Quality | M-Exempt | 30,000 @ $11.03 | $330.9K |
TTM vs. 5-year historical average (annual ratios)
| Metric | AORT | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -390.9x | 3.1x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -86.3x | EPS est. -0.27 | Discount |
| Price / Book | 2.5x | 3.2x | Discount |
| Price / Sales | 2.4x | 2.8x | In line |
| EV / EBITDA | 28.7x | 35.5x | Discount |
| Return on equity | -0.7% | — | Weak |
| Gross margin | 62.8% | 64.1% | In line |
| Debt / Equity | 0.92 | 1.14 | Moderate |
| Piotroski / Altman Z | 3/9 | Z 1.81 | Grey zone |
Discounted cash flow model
Stock news · updated daily
ATLANTA, Oct. 22, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2026 financial results will be released on Thursday, November 5, 2026, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.
Artivion NYSE: AORT reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, as growth in stent grafts and On-X heart valves offset modest declines in BioGlue. Adjusted EBITDA rose about 7% to $26.4 million, while adjusted EBITDA margin declined roughly 90 basis points to 21% amid higher research and development spending and costs related to the Endospan acquisition.
Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript
Artivion (AORT) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.24 per share a year ago.
Second Quarter & Recent Business Highlights: Achieved revenue of $125.8 million in the second quarter of 2026 versus $113.0 million in the second quarter of 2025, an increase of 11% on a GAAP basis and 9% on a non-GAAP constant currency basis Net loss for the second quarter of 2026 was $(13.5) million, or $(0.28) per fully diluted share, and non-GAAP net income was $6.3 million, or $0.13 per fully diluted share Adjusted EBITDA increased 7% to $26.4 million in the second quarter of 2026 compared to $24.8 million in the second quarter of 2025 Announced U.S. FDA PMA Approval of the AMDS Hybrid Prosthesis Completed acquisition of Endospan Ltd. ATLANTA, Aug. 6, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2026.
ATLANTA, July 28, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion's management team will present at the upcoming Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at the InterContinental Boston Hotel.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | 0.00 | -0.28 | Miss -11300.0% | $125.8M |
| May 7, 2026 | 0.06 | 0.03 | Miss -50.0% | $116.3M |
| Feb 12, 2026 | 0.14 | 0.05 | Miss -63.6% | $116.0M |
| Nov 6, 2025 | 0.14 | 0.16 | Beat 14.3% | $113.4M |
| Aug 7, 2025 | 0.11 | 0.03 | Miss -72.5% | $113.0M |
| May 5, 2025 | 0.12 | -0.01 | Miss -108.3% | $98.98M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Sep 11, 2026 | 2026-09-11 17:28:47 | View |
| 4 | Sep 4, 2026 | 2026-09-04 14:15:13 | View |
| 4 | Aug 20, 2026 | 2026-08-20 14:11:04 | View |
| 4 | Aug 17, 2026 | 2026-08-17 15:18:49 | View |
| 4 | Aug 17, 2026 | 2026-08-17 15:17:31 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 13:54:22 | View |
| 4 | Aug 12, 2026 | 2026-08-12 17:51:46 | View |
| 10-Q | Aug 7, 2026 | 2026-08-07 13:57:54 | View |
| 8-K | Aug 6, 2026 | 2026-08-06 16:08:36 | View |
| SC 13G/A | Aug 6, 2026 | 2026-08-06 10:14:37 | View |
Proxy statement (DEF 14A) disclosures
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure